BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

4422 related articles for article (PubMed ID: 12688838)

  • 1. Improving survival in patients with high-risk and metastatic melanoma: immunotherapy leads the way.
    Agarwala S
    Am J Clin Dermatol; 2003; 4(5):333-46. PubMed ID: 12688838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Melanoma: immunotherapeutic approaches.
    Agarwala SS; Kirkwood JM
    BioDrugs; 1999 Sep; 12(3):193-208. PubMed ID: 18031176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined chemoimmunotherapy in metastatic melanoma--is there a need for the double?
    Schrader AJ
    Anticancer Drugs; 2000 Mar; 11(3):143-8. PubMed ID: 10831272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of interferon-alpha in the treatment of cutaneous melanoma: a review.
    Punt CJ
    Melanoma Res; 1998 Apr; 8(2):95-104. PubMed ID: 9610861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy as an adjuvant therapy in the management of advanced, surgically resected, melanoma.
    Kalani AD; Jack A; Montenegro G; Degliuomini J; Wallack MK
    G Ital Dermatol Venereol; 2008 Feb; 143(1):59-70. PubMed ID: 18833052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melanoma adjuvant therapy.
    Tarhini AA; Thalanayar PM
    Hematol Oncol Clin North Am; 2014 Jun; 28(3):471-89. PubMed ID: 24880942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
    Iversen TZ
    Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma.
    Mitchell MS; Abrams J; Thompson JA; Kashani-Sabet M; DeConti RC; Hwu WJ; Atkins MB; Whitman E; Ernstoff MS; Haluska FG; Jakowatz JG; Das Gupta TK; Richards JM; Samlowski WE; Costanzi JJ; Aronson FR; Deisseroth AB; Dudek AZ; Jones VE
    J Clin Oncol; 2007 May; 25(15):2078-85. PubMed ID: 17513813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
    Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
    Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokine-based therapy and biochemotherapy for advanced melanoma.
    Atkins MB
    Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2353s-2358s. PubMed ID: 16609058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma.
    Flaherty LE
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S15-20. PubMed ID: 10685653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of metastatic malignant melanoma.
    Atallah E; Flaherty L
    Curr Treat Options Oncol; 2005 May; 6(3):185-93. PubMed ID: 15869730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.
    Keilholz U; Stoter G; Punt CJ; Scheibenbogen C; Lejeune F; Eggermont AM
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S22-8. PubMed ID: 9457389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant therapy for high-risk primary and resected metastatic melanoma.
    Hersey P
    Intern Med J; 2003; 33(1-2):33-43. PubMed ID: 12534876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermediate- and high-risk melanoma.
    Agarwala SS
    Curr Treat Options Oncol; 2002 Jun; 3(3):205-17. PubMed ID: 12057066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metastatic melanoma.
    Sun W; Schuchter LM
    Curr Treat Options Oncol; 2001 Jun; 2(3):193-202. PubMed ID: 12057119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of metastatic melanoma: an overview.
    Bhatia S; Tykodi SS; Thompson JA
    Oncology (Williston Park); 2009 May; 23(6):488-96. PubMed ID: 19544689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy: Vaccine trials in melanoma -- time for reflection.
    Eggermont AM
    Nat Rev Clin Oncol; 2009 May; 6(5):256-8. PubMed ID: 19390551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant therapy of melanoma.
    Agarwala SS; Kirkwood JM
    Semin Surg Oncol; 1998 Jun; 14(4):302-10. PubMed ID: 9588723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 222.